{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:18:15Z","timestamp":1784809095881,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Commercially available saponins are extracted from <jats:italic>Quillaja saponaria<\/jats:italic> barks, being Quil A<jats:sup>\u00ae<\/jats:sup> the most widely used. Nanoparticulate immunostimulating complexes (ISCOMs or ISCOMATRIX) formulated with these, are able to stimulate strong humoral and cellular immune responses. Recently, we formulated novel ISCOMs replacing QuilA<jats:sup>\u00ae<\/jats:sup> by QB-90 (IQB-90), a <jats:italic>Quillaja brasiliensis<\/jats:italic> leaf-extracted saponin fraction, and reported that IQB-90 improved antigen uptake, and induced systemic and mucosal antibody production, and T-cell responses. However, its mechanism of action remains unclear. In this study we provide a deeper insight into the immune stimulatory properties of QB-90 and ISCOMATRIX-like based on this fraction (IMXQB-90). We show herein that, when used as a viral vaccine adjuvant, QB-90 promotes an \u201cimmunocompetent environment\u201d. In addition, QB-90 and IMXQB-90 induce immune-cells recruitment at draining-lymph nodes and spleen. Subsequently, we prove that QB-90 or IMXQB-90 stimulated dendritic cells secret IL-1\u03b2 by mechanisms involving Caspase-1\/11 and MyD88 pathways, implying canonical inflammasome activation. Finally, both formulations induce a change in the expression of cytokines and chemokines coding genes, many of which are up-regulated. Findings reported here provide important insights into the molecular and cellular mechanisms underlying the adjuvant activity of <jats:italic>Q<\/jats:italic>. <jats:italic>brasiliensis<\/jats:italic> leaf-saponins and its respective nanoparticles.<\/jats:p>","DOI":"10.1038\/s41598-018-31995-1","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T10:12:34Z","timestamp":1536142354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses"],"prefix":"10.1038","volume":"8","author":[{"given":"Samuel Paulo","family":"Cibulski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Rivera-Patron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Mourglia-Ettlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Casaravilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carolina Alves","family":"Yendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Germano","family":"Fett-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alejandro","family":"Chabalgoity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-7661","authenticated-orcid":false,"given":"Paulo Michel","family":"Roehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-8265","authenticated-orcid":false,"given":"Fernando","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"31995_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","volume":"38","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky, N. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Safety 38, 1059\u20131074 (2015).","journal-title":"Drug Safety"},{"key":"31995_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13324","volume":"7","author":"MH den Brok","year":"2016","unstructured":"den Brok, M. H. et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nature Communications 7, 13324 (2016).","journal-title":"Nature Communications"},{"key":"31995_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","volume":"291","author":"R Marty-Roix","year":"2016","unstructured":"Marty-Roix, R. et al. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants. Journal of Biological Chemistry 291, 1123\u20131136 (2016).","journal-title":"Journal of Biological Chemistry"},{"key":"31995_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep39475","volume":"6","author":"S Detienne","year":"2016","unstructured":"Detienne, S. et al. Central Role of CD169(+) Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01. Scientific reports 6, 39475 (2016).","journal-title":"Scientific reports"},{"key":"31995_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.007","volume":"28","author":"E Oleszycka","year":"2014","unstructured":"Oleszycka, E. & Lavelle, E. C. Immunomodulatory properties of the vaccine adjuvant alum. Current Opinion in Immunology 28, 1\u20135 (2014).","journal-title":"Current Opinion in Immunology"},{"key":"31995_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","volume":"169","author":"G Leroux-Roels","year":"2016","unstructured":"Leroux-Roels, G. et al. Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clinical Immunology 169, 16\u201327 (2016).","journal-title":"Clinical Immunology"},{"key":"31995_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","volume":"47","author":"DT O\u2019Hagan","year":"2017","unstructured":"O\u2019Hagan, D. T., Friedland, L. R., Hanon, E. & Didierlaurent, A. M. Towards an evidence based approach for the development of adjuvanted vaccines. Current Opinion in Immunology 47, 93\u2013102 (2017).","journal-title":"Current Opinion in Immunology"},{"key":"31995_CR8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","volume":"6","author":"I Delany","year":"2014","unstructured":"Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Molecular Medicine 6, 708\u2013720 (2014).","journal-title":"EMBO Molecular Medicine"},{"key":"31995_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14760584.2017.1306440","volume":"16","author":"N Chauhan","year":"2017","unstructured":"Chauhan, N., Tiwari, S., Iype, T. & Jain, U. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators. Expert Review of Vaccines 16, 491\u2013502 (2017).","journal-title":"Expert Review of Vaccines"},{"key":"31995_CR10","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","volume":"27","author":"HX Sun","year":"2009","unstructured":"Sun, H. X., Xie, Y. & Ye, Y. P. Advances in saponin-based adjuvants. Vaccine 27, 1787\u20131796 (2009).","journal-title":"Vaccine"},{"key":"31995_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jsps.2011.06.003","volume":"19","author":"SM Sivakumar","year":"2011","unstructured":"Sivakumar, S. M., Safhi, M. M., Kannadasan, M. & Sukumaran, N. Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharmaceutical Journal 19, 197\u2013206 (2011).","journal-title":"Saudi Pharmaceutical Journal"},{"key":"31995_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","volume":"38","author":"SR Bonam","year":"2017","unstructured":"Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M. & Muller, S. An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. Trends in Pharmacological Sciences 38, 771\u2013793 (2017).","journal-title":"Trends in Pharmacological Sciences"},{"key":"31995_CR13","doi-asserted-by":"publisher","first-page":"e0154757","DOI":"10.1371\/journal.pone.0154757","volume":"11","author":"E Bigaeva","year":"2016","unstructured":"Bigaeva, E., Doorn, E., van, Liu, H. & Hak, E. Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability. Plos One 11, e0154757 (2016).","journal-title":"Plos One"},{"key":"31995_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1586\/erv.11.18","volume":"10","author":"G Ragupathi","year":"2011","unstructured":"Ragupathi, G., Gardner, J. R., Livingston, P. O. & Gin, D. Y. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert review of vaccines 10, 463\u201370 (2011).","journal-title":"Expert review of vaccines"},{"key":"31995_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.4161\/hv.27907","volume":"10","author":"R Buglione-Corbett","year":"2014","unstructured":"Buglione-Corbett, R. et al. Reduced MyD88 dependency of ISCOMATRIXTM adjuvant in a DNA prime-protein boost HIV vaccine. Human Vaccines and Immunotherapeutics 10, 1078\u20131090 (2014).","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"31995_CR16","first-page":"1","volume":"584","author":"AM Didierlaurent","year":"2016","unstructured":"Didierlaurent, A. M. et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert review of vaccines 584, 1\u20139 (2016).","journal-title":"Expert review of vaccines"},{"key":"31995_CR17","first-page":"153","volume":"8","author":"C Kauffmann","year":"2004","unstructured":"Kauffmann, C. et al. Constituents from leaves of Quillaja brasiliensis. Natural productresearch1 8, 153\u20137 (2004).","journal-title":"Natural productresearch1"},{"key":"31995_CR18","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.1016\/j.vaccine.2006.06.059","volume":"24","author":"JD Fleck","year":"2006","unstructured":"Fleck, J. D. et al. Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice. Vaccine 24, 7129\u20137134 (2006).","journal-title":"Vaccine"},{"key":"31995_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.phytol.2017.04.020","volume":"20","author":"F Wallace","year":"2017","unstructured":"Wallace, F., Bennadji, Z., Ferreira, F. & Olivaro, C. Analysis of an immunoadjuvant saponin fraction from Quillaja brasiliensis leaves by electrospray ionization ion trap multiple-stage mass spectrometry. Phytochemistry Letters 20, 228\u2013233 (2017).","journal-title":"Phytochemistry Letters"},{"key":"31995_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.vaccine.2017.11.030","volume":"36","author":"S Cibulski","year":"2017","unstructured":"Cibulski, S. et al. Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines. Vaccine 36, 55\u201365 (2017).","journal-title":"Vaccine"},{"key":"31995_CR21","doi-asserted-by":"publisher","first-page":"9177","DOI":"10.1016\/j.vaccine.2011.09.137","volume":"29","author":"F Silveira","year":"2011","unstructured":"Silveira, F. et al. Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation. Vaccine 29, 9177\u20139182 (2011).","journal-title":"Vaccine"},{"key":"31995_CR22","first-page":"1","volume":"9","author":"F De Costa","year":"2014","unstructured":"De Costa, F. et al. Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-A saponins are equally effective in inducing specific immune responses. PLoS ONE 9, 1\u20137 (2014).","journal-title":"PLoS ONE"},{"key":"31995_CR23","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.vaccine.2016.03.070","volume":"34","author":"ACA Yendo","year":"2016","unstructured":"Yendo, A. C. A. et al. A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge. Vaccine 34, 2305\u20132311 (2016).","journal-title":"Vaccine"},{"key":"31995_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cimid.2016.01.004","volume":"45","author":"SP Cibulski","year":"2016","unstructured":"Cibulski, S. P. et al. Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice. Comparative Immunology, Microbiology and Infectious Diseases 45, 1\u20138 (2016).","journal-title":"Comparative Immunology, Microbiology and Infectious Diseases"},{"key":"31995_CR25","doi-asserted-by":"publisher","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","volume":"33S","author":"DT O\u2019Hagan","year":"2015","unstructured":"O\u2019Hagan, D. T. & Fox, C. B. New generation adjuvants \u2013 From empiricism to rational design. Vaccine 33S, B14\u2013B20 (2015).","journal-title":"Vaccine"},{"key":"31995_CR26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-118387","author":"C de Groot","year":"2016","unstructured":"de Groot, C. & Muller-Goymann, C. C. Saponin Interactions with Model Membrane Systems - Langmuir Monolayer Studies, Hemolysis and Formation of ISCOMs. Planta Medica. https:\/\/doi.org\/10.1055\/s-0042-118387 (2016).","journal-title":"Planta Medica"},{"key":"31995_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4161\/hv.6.3.10754","volume":"6","author":"A McKenzie","year":"2010","unstructured":"McKenzie, A., Watt, M. & Gittleson, C. ISCOMATRIX vaccines: Safety in human clinical studies. Human vaccines 6, 237\u2013246 (2010).","journal-title":"Human vaccines"},{"key":"31995_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/308457a0","volume":"308","author":"B Morein","year":"1984","unstructured":"Morein, B., Sundquist, B., H\u00f6glund, S. & Dalsgaard, K. & Osterhaus, a. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457\u2013460 (1984).","journal-title":"Nature"},{"key":"31995_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/icb.2009.21","volume":"87","author":"E Maraskovsky","year":"2009","unstructured":"Maraskovsky, E. et al. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunology and cell biology 87, 371\u20136 (2009).","journal-title":"Immunology and cell biology"},{"key":"31995_CR30","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","volume":"27","author":"HX Sun","year":"2009","unstructured":"Sun, H. X., Xie, Y. & Ye, Y. P. ISCOMs and ISCOMATRIXTM. Vaccine 27, 4388\u20134401 (2009).","journal-title":"Vaccine"},{"key":"31995_CR31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1099\/jmm.0.040857-0","volume":"61","author":"AB Morelli","year":"2012","unstructured":"Morelli, A. B. et al. ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. Journal of Medical Microbiology 61, 935\u2013943 (2012).","journal-title":"Journal of Medical Microbiology"},{"key":"31995_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4161\/hv.5.3.6614","volume":"5","author":"D Drane","year":"2009","unstructured":"Drane, D. et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 5, 151\u2013157 (2009).","journal-title":"Hum Vaccin"},{"key":"31995_CR33","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1016\/j.vaccine.2009.04.037","volume":"27","author":"HX Sun","year":"2009","unstructured":"Sun, H. X., Wang, H. & Xu, H. shun & Ni, Y. Novel polysaccharide adjuvant from the roots of Actinidia eriantha with dual Th1 and Th2 potentiating activity. Vaccine 27, 3984\u20133991 (2009).","journal-title":"Vaccine"},{"key":"31995_CR34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.vaccine.2016.01.029","volume":"34","author":"SP Cibulski","year":"2016","unstructured":"Cibulski, S. P. et al. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake. Vaccine 34, 1162\u20131171 (2016).","journal-title":"Vaccine"},{"key":"31995_CR35","doi-asserted-by":"crossref","unstructured":"Morelli, A. B. & Maraskovsky, E. In Immunopotentiators In Modern Vaccines (eds Schijns, V. E. J. C. & O\u2019Hagan, D. T.) 311\u2013332 (2016).","DOI":"10.1016\/B978-0-12-804019-5.00016-5"},{"key":"31995_CR36","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.4049\/jimmunol.1302011","volume":"192","author":"NS Wilson","year":"2014","unstructured":"Wilson, N. S. et al. Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant. Journal of immunology (Baltimore, Md. : 1950) 192, 3259\u201368 (2014).","journal-title":"Journal of immunology (Baltimore, Md. : 1950)"},{"key":"31995_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4049\/jimmunol.1004114","volume":"187","author":"P Duewell","year":"2011","unstructured":"Duewell, P. et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. Journal of immunology (Baltimore, Md.: 1950) 187, 55\u201363 (2011).","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"key":"31995_CR38","doi-asserted-by":"publisher","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","volume":"7","author":"JM Reimer","year":"2012","unstructured":"Reimer, J. M. et al. Matrix-MTM adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PloS one 7, e41451 (2012).","journal-title":"PloS one"},{"key":"31995_CR39","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","volume":"31","author":"SE Magnusson","year":"2013","unstructured":"Magnusson, S. E. et al. Immune enhancing properties of the novel Matrix-TM adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31, 1725\u20131733 (2013).","journal-title":"Vaccine"},{"key":"31995_CR40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/14760584.6.5.761","volume":"6","author":"D Drane","year":"2007","unstructured":"Drane, D., Gittleson, C., Boyle, J. & Maraskovsky, E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert review of vaccines 6, 761\u201372 (2007).","journal-title":"Expert review of vaccines"},{"key":"31995_CR41","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1073\/pnas.0804699105","volume":"105","author":"F Mosca","year":"2008","unstructured":"Mosca, F. et al. Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America 105, 10501\u20136 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"31995_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0264-410X(95)00182-Z","volume":"14","author":"RK Gupta","year":"1996","unstructured":"Gupta, R. K., Varanelli, C. L., Griffin, P., Wallach, D. F. H. & Siber, G. R. Adjuvant properties of non-phospholipid liposomes (Novasomes\u00ae) in experimental animals for human vaccine antigens. Vaccine 14, 219\u2013225 (1996).","journal-title":"Vaccine"},{"key":"31995_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","volume":"6","author":"G Ott","year":"1995","unstructured":"Ott, G. et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccinne. Pharm Biotechnol 6, 277\u2013296 (1995).","journal-title":"Pharm Biotechnol"},{"key":"31995_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/icb.2011.71","volume":"90","author":"NS Wilson","year":"2012","unstructured":"Wilson, N. S. et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunology and Cell Biology 90, 540\u2013552 (2012).","journal-title":"Immunology and Cell Biology"},{"key":"31995_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1189\/jlb.1012540","volume":"94","author":"S Schuster","year":"2013","unstructured":"Schuster, S., Hurrell, B. & Tacchini-Cottier, F. Crosstalk between neutrophils and dendritic cells: a context-dependent process. Journal of leukocyte biology 94, 671\u20135 (2013).","journal-title":"Journal of leukocyte biology"},{"key":"31995_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erv.12.140","volume":"12","author":"DT O\u2019Hagan","year":"2013","unstructured":"O\u2019Hagan, D. T. et al. Del. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert review of vaccines 12, 13\u201330 (2013).","journal-title":"Expert review of vaccines"},{"key":"31995_CR47","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812\u20131823 (2011).","journal-title":"Vaccine"},{"key":"31995_CR48","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","volume":"132","author":"KS Campbell","year":"2013","unstructured":"Campbell, K. S. & Hasegawa, J. Natural killer cell biology: An update and future directions. Journal of Allergy and Clinical Immunology 132, 536\u2013544 (2013).","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"31995_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"E-K Jo","year":"2016","unstructured":"Jo, E.-K., Kim, J. K., Shin, D.-M. & Sasakawa, C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cellular & molecular immunology 13, 148\u201359 (2016).","journal-title":"Cellular & molecular immunology"},{"key":"31995_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","volume":"181","author":"H Li","year":"2008","unstructured":"Li, H., Willingham, S. B., Ting, J. P.-Y. & Re, F. Cutting Edge: Inflammasome Activation by Alum and Alum\u2019s Adjuvant Effect Are Mediated by NLRP3. The Journal of Immunology 181, 17\u201321 (2008).","journal-title":"The Journal of Immunology"},{"key":"31995_CR51","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT O\u2019Hagan","year":"2012","unstructured":"O\u2019Hagan, D. T., Ott, G. S., De Gregorio, E. & Seubert, A. The mechanism of action of MF59 - An innately attractive adjuvant formulation. Vaccine 30, 4341\u20134348 (2012).","journal-title":"Vaccine"},{"key":"31995_CR52","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","volume":"180","author":"A Seubert","year":"2008","unstructured":"Seubert, A., Monaci, E., Pizza, M., O\u2019Hagan, D. T. & Wack, A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. Journal of immunology (Baltimore, Md.: 1950) 180, 5402\u20135412 (2008).","journal-title":"Journal of immunology (Baltimore, Md.: 1950)"},{"key":"31995_CR53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1211\/0022357056280","volume":"57","author":"DG Lendemans","year":"2005","unstructured":"Lendemans, D. G., Myschik, J., Hook, S. & Rades, T. Immuno-stimulating complexes prepared by ethanol injection. Journal of Pharmacy and Pharmacology 57, 729\u2013733 (2005).","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"31995_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","volume":"223","author":"MB Lutz","year":"1999","unstructured":"Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Journal of Immunological Methods 223, 77\u201392 (1999).","journal-title":"Journal of Immunological Methods"},{"key":"31995_CR55","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research 29, e45 (2001).","journal-title":"Nucleic acids research"},{"key":"31995_CR56","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","volume":"45","author":"D Szklarczyk","year":"2017","unstructured":"Szklarczyk, D. et al. The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Research 45, D362\u2013D368 (2017).","journal-title":"Nucleic Acids Research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31995-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:16:40Z","timestamp":1671614200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31995-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31995"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31995-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"3 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13582"}}